MNI: PBOC Conducts CNY2 Bln Via OMO Thurs; Liquidity Unchanged

CHINA PBOC CONDUCTS CNY2 BILLION VIA 7-DAY REVERSE REPOS THURS

MNI: PBOC Sets Yuan Parity Lower At 7.1339 Thurs; -1.06% Y/Y

CHINA SETS YUAN CENTRAL PARITY AT 7.1339 THURS VS 7.1342

MNI BRIEF: Bank of Korea Keeps Policy Rate At 3.50%

MNI: BANK OF KOREA KEEPS POLICY RATE AT 3.50%: PRESS

Japan May Machine Orders -3.2% M/M

MNI JAPAN MAY CORE MACHINE ORDERS -3.2% M/M; APRIL -2.9%

EZ/UK T-Bill Calendar: 1/3/6-Month UKTB Auction on Friday

RPT-MNI: Canada Sticks To Fiscal Anchors, Spends Chunk Of Windfall

MNI BRIEF: Poilievre Calls QE 'Scam' And Would Limit BOC Remit

© 1982-2024 MNI. All rights reserved.
Terms | Privacy
Log Out
Free Trial

Boston Scientific (BSX; Baa1, BBB+, BBB+; S) {BSX US Equity}

HEALTHCARE
Credit BulletsBulletHomepagemarkets-real-timeCredit
  • Strong beat with headline sales at $3.86b (c$3.68b) up +14%yoy (c+8.7%) & EBITDA at $1.23b (c$1.07b). Analyst seem well optimistic on the release.
  • FCF in Q1 was -15m on $179m capex netting $164m of operating cash flows. "Estimated" operating cash flow in FY24 is unch at ~$2.7b with $700m in net capex netting $2b in FCF. Gross leverage sat at 2.55x, up from 2.3x last qtr - gross debt includes €2b debt raised to partially fund Axonics acquisition announced early this year (for $3.7b).
  • Headline guidance is firm; for Q2 at net sales growth of 10.5-12.5% & for FY24 at 11-13%. Organic growth around -1% shy on those rates.
108 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.
  • Strong beat with headline sales at $3.86b (c$3.68b) up +14%yoy (c+8.7%) & EBITDA at $1.23b (c$1.07b). Analyst seem well optimistic on the release.
  • FCF in Q1 was -15m on $179m capex netting $164m of operating cash flows. "Estimated" operating cash flow in FY24 is unch at ~$2.7b with $700m in net capex netting $2b in FCF. Gross leverage sat at 2.55x, up from 2.3x last qtr - gross debt includes €2b debt raised to partially fund Axonics acquisition announced early this year (for $3.7b).
  • Headline guidance is firm; for Q2 at net sales growth of 10.5-12.5% & for FY24 at 11-13%. Organic growth around -1% shy on those rates.